ImmuniMed Inc. is an innovative, clinical-stage, Research & Development Biopharmaceutical Company. ImmuniMed Inc. develops oral antibody therapy using passive vaccination to treat and prevent gastro-enteric infections. Their technology is designed to utilize chicken eggs as bioreactors to manufacture specific polyclonal antibodies – a new class of biopharmaceuticals.
member
The Government of Canada is investing $2 billion to support diagnostic testing and to purchase ventilators and protective personal equipment, including for bulk purchases with provinces and territories.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.